The rise of copyright’s blockbuster initially sparked a boom for the drug industry, but recent shifts present a complicated outlook for investors. Off-patent versions are reducing profits, and ongoing litigation add https://joanjfbe562618.blogdon.net/the-blue-pill-and-pharma-a-risky-bet-57312830